CHIAO-WEN LINSHUN-FA YANG2026-10-162026-10-162012-11-01Pure ID: 15369976Pure UUID: 2108302a-37fa-4ff1-8cef-2267e754e0c010.1111/j.1601-0825.2012.01938.xhttps://www.scopus.com/pages/publications/84866871900https://scholars.csmu.edu.tw/handle/123456789/31907Objectives: Recent evidence demonstrated that lipocalin (LCN)2 is induced in many types of human cancer, while the detection of its complex with matrix metalloproteinase (MMP)-9 is correlated with the cancer disease status. We attempted to evaluate plasma expressions of LCN2, MMP-9, and their complex (LCN2/MMP-9) during the diagnostic work-up of patients with oral squamous cell carcinoma (OSCC) and investigated their correlations with disease progression. Methods: In total, 195 patients with OSCC and 81 healthy controls were recruited. Expression levels of LCN2, MMP-9, and LCN2/MMP-9 were determined with immunoenzymatic assays. Results: Patients with OSCC exhibited significantly higher levels of LCN2, MMP-9, and LCN2/MMP-9 compared with healthy controls (LCN2: P<0.001; MMP-9: P<0.001; LCN2/MMP-9: P<0.01). Plasma levels of LCN2, MMP-9, and LCN2/MMP-9 in patients with OSCC were significantly correlated with each other and were associated with more-advanced clinical stages (P<0.05) and/or a larger tumor size (P<0.05), but were not associated with positive lymph-node metastasis or distal metastasis. Conclusion: Our results suggest that plasma levels of LCN2 and the LCN2/MMP-9 complex may be useful in non-invasively monitoring OSCC progression, while supporting their potential role as biomarkers of oral cancer disease status.7enjournal article